Pharmaceutical manufacturers and payers have been involved in a back and forth dance regarding patient cost share practices - each action is met with a reaction. Precision's Jeremy Schafer looks at the complex battle between pharmaceutical manufacturers and payers for balance between medication access and budget management.
Access challenges to cell and gene therapy are well documented. Precision's Christina Poschen and David Carr discuss how some innovative manufacturers are moving away from the role of being purely a researcher and manufacturer and toward involvement at the point of diagnosis through manufacturing and delivery to patient access support in order to address those challenges head on.
Who typically has responsibility for Identity and Access Management within health plan organizations, and how does this role impact or protect their healthcare analytics objectives? Precision's Dominic Galante contributes to the Thought Leaders Corner in this month's Care Analytics News.
Precision's Avi Mamidi discusses the benefits and obstacles of cutting out health insurance middlemen and moving towards direct partnerships between Integrated Delivery Networks (IDNs) and employers.
Precision's Elizabeth Oyekan identifies four emerging trends in alternative payment models (APM) practices that are enabling APMs to be better prepared to deliver high-quality and more affordable care during the COVID-19 pandemic.
Precision's Andrew Cournoyer discusses our research results on the effects of the shift to virtual negotiations between pharma and payers as a result of the COVID-19 pandemic, and the challenges they face going forward.
COVID-19 has exacerbated fractures in our healthcare and social delivery systems, including adverse social risk factors. Precision's Maureen Hennessey discusses strategies pharmaceutical manufacturers must adopt to address social determinants of health and population health management challenges during the COVID-19 pandemic and beyond.
Precision's Jeremy Schafer and Deborah Lotterman discuss how to use vaccine messaging based on our shared coronavirus experiences to improve vaccination rates and educate the public on their importance.
Orphan drugs make up a growing slice of the pharmaceutical pipeline, with a significant share of new drug approvals, and payers are taking notice of their increasing market numbers and ultra-expensive price tags. Precision's Jeremy Schafer, PharmD, MBA, discusses how manufacturers may adjust their promotion of orphan drugs to ensure continued market access.
How much of a role can pharmaceutical manufacturers play in the social determinants of health? Industry experts, Maureen Hennessey, PhD, and Dominic Galante, MD, discuss how much they can stand to gain in medication adherence and outcomes from partnering with other industry stakeholders and programs around the issue.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
